Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2012 Apr 12:7:20.
doi: 10.1186/1750-1172-7-20.

Behçet's disease

David Saadoun  1 , Bertrand Wechsler
Affiliations
Review

Behçet's disease

David Saadoun et al. Orphanet J Rare Dis. .

Abstract

DEFINITION OF THE DISEASE: Behçet disease (BD) is a chronic, relapsing, multisystemic disorder characterized by mucocutaneous, ocular, vascular and central nervous system manifestations.

Epidemiology: BD seems to cluster along the ancient Silk Road, which extends from eastern Asia to the Mediterranean basin. European cases are often described, not exclusively in the migrant population.

Clinical description: The clinical spectrum includes oral and genital ulcerations, uveitis, vascular, neurological, articular, renal and gastrointestinal manifestations.

Etiology: The etiopathogenesis of the disease remains unknown, although genetic predisposition, environmental factors and immunological abnormalities have been implicated.

Diagnostic methods: Diagnosis is only based on clinical criteria. DIFFERRENTIAL DIAGNOSIS: It depends on the clinical presentation of BD, but sarcoidosis, multiple sclerosis, Crohn's disease, Takayasu's arteritis, polychondritis or antiphospholipid syndrome need to be considered.

Management: Treatment is symptomatic using steroids and immunomodulatory therapy. It is efficient depending on the rapidity of initiation, the compliance, and the duration of therapy.

Prognosis: The prognosis is severe due to the ocular, neurological and arterial involvement.

PubMed Disclaimer

References

    1. Zouboulis CC, Keitel W. A historical review of early descriptions of Adamantiades-Behcet's disease. J Invest Dermatol. 2002;119(1):201–205. doi: 10.1046/j.1523-1747.2002.01798.x. - DOI - PubMed
    1. McGonagle D, McDermott MF. A proposed classification of the immunological diseases. PLoS Med. 2006;3(8):e297. doi: 10.1371/journal.pmed.0030297. - DOI - PMC - PubMed
    1. Criteria for diagnosis of Behcet's disease. International Study Group for Behcet's Disease. Lancet. 1990;335(8697):1078–1080. - PubMed
    1. Ohno S, Ohguchi M, Hirose S, Matsuda H, Wakisaka A, Aizawa M. Close association of HLA-Bw51 with Behcet's disease. Arch Ophthalmol. 1982;100(9):1455–1458. doi: 10.1001/archopht.1982.01030040433013. - DOI - PubMed
    1. Verity DH, Wallace GR, Vaughan RW, Kondeatis E, Madanat W, Zureikat H, Fayyad F, Marr JE, Kanawati CA, Stanford MR. HLA and tumour necrosis factor (TNF) polymorphisms in ocular Behcet's disease. Tissue Antigens. 1999;54(3):264–272. doi: 10.1034/j.1399-0039.1999.540307.x. - DOI - PubMed